Stephens Consulting LLC Cuts Stock Position in Pfizer Inc. (NYSE:PFE)

Stephens Consulting LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 24.6% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 3,654 shares of the biopharmaceutical company’s stock after selling 1,191 shares during the period. Stephens Consulting LLC’s holdings in Pfizer were worth $101,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. GoalVest Advisory LLC lifted its position in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC boosted its position in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares in the last quarter. VisionPoint Advisory Group LLC grew its stake in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the last quarter. Finally, Tennessee Valley Asset Management Partners acquired a new position in Pfizer during the 4th quarter valued at about $36,000. 68.36% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

PFE has been the subject of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, June 26th. BMO Capital Markets reissued an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Morgan Stanley raised their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Finally, Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $35.54.

Pfizer Stock Performance

NYSE PFE opened at $27.98 on Monday. The stock has a market capitalization of $158.55 billion, a price-to-earnings ratio of -466.26, a PEG ratio of 1.10 and a beta of 0.69. The stock has a 50-day moving average of $27.90 and a 200 day moving average of $27.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80.

Pfizer (NYSE:PFE) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. During the same quarter last year, the firm posted $1.23 earnings per share. Pfizer’s revenue was down 19.5% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Thursday, July 25th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is presently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.